vs
Side-by-side financial comparison of Bone Biologics Corp (BBLG) and PLIANT THERAPEUTICS, INC. (PLRX). Click either name above to swap in a different company.
Bone Biologics Corp is a clinical-stage biotechnology firm focused on developing orthobiologic products to boost bone regeneration and healing for orthopedic surgery patients, including spinal fusion recipients. It mainly operates in the U.S. healthcare market, targeting orthopedic care and regenerative medicine segments.
Pliant Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing novel targeted therapies for fibrotic diseases. Its pipeline includes candidate treatments for idiopathic pulmonary fibrosis, liver fibrosis and other chronic fibrotic conditions, with primary U.S. operations focused on addressing global unmet patient medical needs.
BBLG vs PLRX — Head-to-Head
Income Statement — Q1 FY2024 vs Q4 FY2024
| Metric | | |
|---|---|---|
| Revenue | $255 | $0 |
| Net Profit | $-866.0K | $-49.7M |
| Gross Margin | — | — |
| Operating Margin | -354327.8% | — |
| Net Margin | -339596.1% | — |
| Revenue YoY | -54.1% | — |
| Net Profit YoY | 76.7% | -21.0% |
| EPS (diluted) | $-1.31 | $-0.82 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | $255 | $0 | ||
| Q4 23 | $348 | $0 | ||
| Q3 23 | $536 | $0 | ||
| Q2 23 | $428 | $248.0K | ||
| Q1 23 | $556 | $1.3M |
| Q4 24 | — | $-49.7M | ||
| Q3 24 | — | $-57.8M | ||
| Q2 24 | — | $-55.9M | ||
| Q1 24 | $-866.0K | $-47.0M | ||
| Q4 23 | $-1.5M | $-41.1M | ||
| Q3 23 | $-1.9M | $-41.5M | ||
| Q2 23 | $-1.8M | $-41.2M | ||
| Q1 23 | $-3.7M | $-37.5M |
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -354327.8% | — | ||
| Q4 23 | -333335.6% | — | ||
| Q3 23 | -388225.7% | — | ||
| Q2 23 | -710249.5% | -19083.9% | ||
| Q1 23 | -566103.8% | -3160.3% |
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -339596.1% | — | ||
| Q4 23 | -445369.3% | — | ||
| Q3 23 | -358154.7% | — | ||
| Q2 23 | -413373.4% | -16609.7% | ||
| Q1 23 | -667248.0% | -2818.9% |
| Q4 24 | — | $-0.82 | ||
| Q3 24 | — | $-0.95 | ||
| Q2 24 | — | $-0.92 | ||
| Q1 24 | $-1.31 | $-0.78 | ||
| Q4 23 | $31.30 | $-0.68 | ||
| Q3 23 | $-4.90 | $-0.70 | ||
| Q2 23 | $-5.21 | $-0.70 | ||
| Q1 23 | $-55.20 | $-0.67 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $355.7M |
| Total DebtLower is stronger | — | $30.2M |
| Stockholders' EquityBook value | $3.7M | $304.1M |
| Total Assets | $3.8M | $396.9M |
| Debt / EquityLower = less leverage | — | 0.10× |
8-quarter trend — quarters aligned by calendar period.
| Q4 24 | — | $355.7M | ||
| Q3 24 | — | $404.5M | ||
| Q2 24 | — | $436.6M | ||
| Q1 24 | — | $482.4M | ||
| Q4 23 | — | $494.2M | ||
| Q3 23 | — | $523.6M | ||
| Q2 23 | — | $555.2M | ||
| Q1 23 | $6.2M | $577.3M |
| Q4 24 | — | $30.2M | ||
| Q3 24 | — | $30.1M | ||
| Q2 24 | — | $30.1M | ||
| Q1 24 | — | $30.0M | ||
| Q4 23 | — | $10.1M | ||
| Q3 23 | — | $10.0M | ||
| Q2 23 | — | $10.0M | ||
| Q1 23 | — | $10.0M |
| Q4 24 | — | $304.1M | ||
| Q3 24 | — | $345.8M | ||
| Q2 24 | — | $392.7M | ||
| Q1 24 | $3.7M | $437.3M | ||
| Q4 23 | $2.9M | $473.6M | ||
| Q3 23 | $3.8M | $503.0M | ||
| Q2 23 | $5.7M | $533.1M | ||
| Q1 23 | $2.8M | $561.9M |
| Q4 24 | — | $396.9M | ||
| Q3 24 | — | $445.7M | ||
| Q2 24 | — | $483.7M | ||
| Q1 24 | $3.8M | $521.6M | ||
| Q4 23 | $3.7M | $512.2M | ||
| Q3 23 | $5.0M | $540.5M | ||
| Q2 23 | $7.6M | $574.9M | ||
| Q1 23 | $6.8M | $597.9M |
| Q4 24 | — | 0.10× | ||
| Q3 24 | — | 0.09× | ||
| Q2 24 | — | 0.08× | ||
| Q1 24 | — | 0.07× | ||
| Q4 23 | — | 0.02× | ||
| Q3 23 | — | 0.02× | ||
| Q2 23 | — | 0.02× | ||
| Q1 23 | — | 0.02× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-1.3M | $-47.7M |
| Free Cash FlowOCF − Capex | — | $-47.9M |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-159.4M |
8-quarter trend — quarters aligned by calendar period.
| Q4 24 | — | $-47.7M | ||
| Q3 24 | — | $-32.3M | ||
| Q2 24 | — | $-45.3M | ||
| Q1 24 | $-1.3M | $-30.3M | ||
| Q4 23 | $-2.0M | $-25.1M | ||
| Q3 23 | $-2.6M | $-36.2M | ||
| Q2 23 | $-3.6M | $-24.8M | ||
| Q1 23 | $-1.3M | $-30.3M |
| Q4 24 | — | $-47.9M | ||
| Q3 24 | — | $-33.2M | ||
| Q2 24 | — | $-46.5M | ||
| Q1 24 | — | $-31.8M | ||
| Q4 23 | — | $-25.2M | ||
| Q3 23 | — | $-36.3M | ||
| Q2 23 | — | $-25.4M | ||
| Q1 23 | — | $-30.4M |
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | -10226.6% | ||
| Q1 23 | — | -2285.2% |
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — | ||
| Q3 23 | — | — | ||
| Q2 23 | — | 243.1% | ||
| Q1 23 | — | 12.2% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
